China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
This article was originally published in PharmAsia News
China's leading contract research organizations, Wuxi PharmaTech and ShangPharma, in a race to win over Big Pharma with integrated service platforms, announced separate deals Oct. 24 to expand into new strategic areas
You may also be interested in...
WuXi PharmaTech forms a joint venture with U.S. contract research organization PRA to grow its clinical capabilities in China; the move expands PRA’s reach to 16 Chinese cities.
After reassessing its China strategy, Charles River makes a new push by acquiring Vital River, the largest supplier of laboratory animals in China.
PharmAsia News takes a closer look at how Chinese healthcare companies have fared against the backdrop of a global economic slowdown, starting with two of the country’s leading companies in their respective industries.